Prevention of Haemophilus influenzae type b disease: Past success and future challenges

Research output: Contribution to journalArticle

Abstract

Haemophilus influenzae type b (Hib) is responsible for significant morbidity and mortality worldwide, particularly in children under 5 years of age. In countries where the Hib conjugate vaccine is not routinely used, Hib is a leading cause of childhood pneumonia and meningitis. Routine use of the Hib conjugate vaccines has resulted in a remarkable decline in Hib disease in developed and developing countries. However, Hib conjugate vaccines are not routinely available in most developing countries, many of which have high burdens of Hib disease. This review outlines the pathogenesis and epidemiology of Hib disease, and the various options for prevention.

Original languageEnglish (US)
Pages (from-to)819-827
Number of pages9
JournalExpert Review of Vaccines
Volume4
Issue number6
DOIs
StatePublished - Dec 2005

Fingerprint

Haemophilus influenzae type b
Conjugate Vaccines
Developing Countries
Meningitis
Developed Countries
Pneumonia
Epidemiology
Morbidity
Mortality

Keywords

  • Developing countries
  • Haemophilus influenzae type b
  • Hib
  • Menegitis
  • Pneumonia
  • Prevention
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Prevention of Haemophilus influenzae type b disease : Past success and future challenges. / Chandran, Aruna; Watt, James P.; Santosham, Mathuram.

In: Expert Review of Vaccines, Vol. 4, No. 6, 12.2005, p. 819-827.

Research output: Contribution to journalArticle

@article{c08f9f763f46421c9a25b10d76239ac9,
title = "Prevention of Haemophilus influenzae type b disease: Past success and future challenges",
abstract = "Haemophilus influenzae type b (Hib) is responsible for significant morbidity and mortality worldwide, particularly in children under 5 years of age. In countries where the Hib conjugate vaccine is not routinely used, Hib is a leading cause of childhood pneumonia and meningitis. Routine use of the Hib conjugate vaccines has resulted in a remarkable decline in Hib disease in developed and developing countries. However, Hib conjugate vaccines are not routinely available in most developing countries, many of which have high burdens of Hib disease. This review outlines the pathogenesis and epidemiology of Hib disease, and the various options for prevention.",
keywords = "Developing countries, Haemophilus influenzae type b, Hib, Menegitis, Pneumonia, Prevention, Vaccines",
author = "Aruna Chandran and Watt, {James P.} and Mathuram Santosham",
year = "2005",
month = "12",
doi = "10.1586/14760584.4.6.819",
language = "English (US)",
volume = "4",
pages = "819--827",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Prevention of Haemophilus influenzae type b disease

T2 - Past success and future challenges

AU - Chandran, Aruna

AU - Watt, James P.

AU - Santosham, Mathuram

PY - 2005/12

Y1 - 2005/12

N2 - Haemophilus influenzae type b (Hib) is responsible for significant morbidity and mortality worldwide, particularly in children under 5 years of age. In countries where the Hib conjugate vaccine is not routinely used, Hib is a leading cause of childhood pneumonia and meningitis. Routine use of the Hib conjugate vaccines has resulted in a remarkable decline in Hib disease in developed and developing countries. However, Hib conjugate vaccines are not routinely available in most developing countries, many of which have high burdens of Hib disease. This review outlines the pathogenesis and epidemiology of Hib disease, and the various options for prevention.

AB - Haemophilus influenzae type b (Hib) is responsible for significant morbidity and mortality worldwide, particularly in children under 5 years of age. In countries where the Hib conjugate vaccine is not routinely used, Hib is a leading cause of childhood pneumonia and meningitis. Routine use of the Hib conjugate vaccines has resulted in a remarkable decline in Hib disease in developed and developing countries. However, Hib conjugate vaccines are not routinely available in most developing countries, many of which have high burdens of Hib disease. This review outlines the pathogenesis and epidemiology of Hib disease, and the various options for prevention.

KW - Developing countries

KW - Haemophilus influenzae type b

KW - Hib

KW - Menegitis

KW - Pneumonia

KW - Prevention

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=29944440591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29944440591&partnerID=8YFLogxK

U2 - 10.1586/14760584.4.6.819

DO - 10.1586/14760584.4.6.819

M3 - Article

C2 - 16372878

AN - SCOPUS:29944440591

VL - 4

SP - 819

EP - 827

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 6

ER -